Pfizer: cross-border access for the specialty portfolio

Quick orientation

Pfizer Inc. is one of the largest US-headquartered research-based pharmaceutical companies, based in New York City. Pfizer's modern specialty footprint is anchored in oncology (significantly expanded by the 2023 Seagen acquisition), rare disease (transthyretin amyloidosis franchise, Array BioPharma BRAF and MEK inhibitors), vaccines, and internal medicine. For cross-border named-patient program activity, the products that surface most often at Reserve Meds intake are high-cost specialty oncology agents, rare-disease cardiomyopathy and hemophilia therapies, and a small set of internal medicine specialty products where international launch sequencing has lagged the US approval.

Portfolio in cross-border NPP scope

Vyndamax and Vyndaqel (tafamidis)

FDA-approved for transthyretin amyloid cardiomyopathy (ATTR-CM), both genetic and wild-type forms. Vyndamax is the 61mg single-capsule daily dose; Vyndaqel is the 80mg (four 20mg capsules) daily dose. US WAC has historically run at approximately $268,000 per patient per year. Cross-border requests are heavy from MENA and India where cardiology specialists have confirmed ATTR-CM by bone scintigraphy but the local payer denies coverage at the wild-type indication, or where the patient's specific TTR mutation places them outside the locally registered subgroup.

Xtandi (enzalutamide)

Androgen receptor inhibitor approved across non-metastatic CRPC, metastatic CRPC, and metastatic castration-sensitive prostate cancer. US WAC at the standard 160mg daily dose runs above $14,500 per month. Reserve Meds coordinates Xtandi most often for patients in India and Egypt routing through international oncology centers, and for patients in the Gulf when the nmCRPC indication is locally restricted to metastatic disease only.

Ibrance (palbociclib)

CDK4/6 inhibitor approved for HR-positive, HER2-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant. US WAC at the 125mg daily three-weeks-on schedule runs at approximately $14,000 per cycle. Cross-border requests cluster around patients in MENA whose payer has restricted formulary access to only one CDK4/6 inhibitor and the treating oncologist has selected palbociclib specifically.

Talzenna (talazoparib)

PARP inhibitor approved as monotherapy for germline BRCA-mutated HER2-negative advanced breast cancer and in combination with enzalutamide for HRR-gene-mutated metastatic CRPC. International requests come predominantly from prostate cancer patients in India and the Gulf where the Talzenna-Xtandi combination has not yet been added to the local label.

Braftovi and Mektovi (encorafenib and binimetinib)

BRAF and MEK inhibitor pair approved for BRAF V600E or V600K-mutant unresectable or metastatic melanoma, and Braftovi additionally for BRAF V600E-mutant metastatic colorectal cancer in combination with cetuximab. Reserve Meds coordinates this combination predominantly for melanoma and CRC patients in MENA where the CRC indication is not yet locally registered.

Padcev (enfortumab vedotin)

Nectin-4-directed antibody-drug conjugate approved (with pembrolizumab) for locally advanced or metastatic urothelial cancer first-line, and as monotherapy after platinum and PD-1/PD-L1 therapy. Cross-border requests cluster around first-line urothelial patients in the Gulf where the Padcev-Keytruda combination is the new standard of care but the combination indication has not yet been locally approved.

Adcetris (brentuximab vedotin)

CD30-directed antibody-drug conjugate approved for classical Hodgkin lymphoma, systemic anaplastic large-cell lymphoma, and cutaneous T-cell lymphomas. Reserve Meds coordinates Adcetris primarily for relapsed and refractory Hodgkin patients in MENA and India where the front-line BV-AVD regimen is not yet locally reimbursed.

BeneFIX, Refacto AF, Genotropin

Pfizer's hemophilia B and hemophilia A replacement factors plus somatropin growth hormone surface periodically through Reserve Meds for pediatric patients where the local market lacks a specific vial-size presentation or where supply shortages have made the brand difficult to source in country.

Why patients route Pfizer products through cross-border NPP

Three patterns drive most Pfizer-specific cross-border demand. First, indication-expansion lag: Pfizer's oncology franchise (particularly the Seagen-origin ADCs Padcev and Adcetris and the Array-origin Braftovi and Mektovi) has expanded indications faster than MENA and India regulators have re-registered each new combination. Patients routing on the latest combination indication often need the FDA-labeled product to support the prescription.

Second, ATTR-CM and rare cardiology coverage gaps: Vyndamax and Vyndaqel coverage in MENA payer systems has historically been narrow, often limited to the genetic-mutation subgroup or requiring an extended diagnostic confirmation step. Patients with confirmed wild-type ATTR-CM routinely route cross-border while they pursue local appeals.

Third, Pfizer's US patient assistance programs (Pfizer RxPathways, the bridge program for Vyndamax) explicitly do not extend to international patients. Cross-border patients on these therapies pay cash through the named-patient pathway; we set this expectation at intake.

Manufacturer engagement posture

Reserve Meds coordinates Pfizer-sourced US product through DSCSA-compliant specialty wholesaler channels. We are not an authorized Pfizer distributor; we are an independent named-patient program coordinator. Pfizer RxPathways and product-specific copay assistance do not extend to cross-border patients. All Reserve Meds orders are cash-pay at firm-quote pricing after clinical documentation review.

For Pfizer market access, medical affairs, and global commercial teams: Reserve Meds maintains structured demand visibility across the Pfizer portfolio by product, indication, and country. If your group is sizing pre-registration demand in MENA and India, or sizing the named-patient demand pool around a planned indication expansion, we are open to a structured conversation under NDA.

Common cross-border destinations for the Pfizer portfolio

The Vyndamax cardiomyopathy franchise concentrates in the UAE, Saudi Arabia, Kuwait, and India. The oncology franchise (Xtandi, Ibrance, Padcev, Adcetris, Braftovi and Mektovi) skews to India, Egypt, Saudi Arabia, and Jordan where oncology centers of excellence carry the highest specialist volume. Pediatric growth-hormone and hemophilia requests originate primarily from the Gulf.

What Reserve Meds provides

For every Pfizer product order, Reserve Meds coordinates DSCSA chain-of-custody documentation from the US specialty wholesaler through to the patient's destination clinician; cold-chain validated logistics where required; country regulatory pathway expertise covering named-patient import approval, customs clearance, and any required physician declaration; and a single patient-facing coordinator who carries the case from initial inquiry through delivery confirmation. We do not replace the patient's treating physician. A US-licensed pharmacist reviews every prescription before the order is released for dispensing.

Next step for patients

Patients or caregivers who have a treating physician's prescription for a Pfizer product and want a firm quote can start a request below.

Start a request for a Pfizer product

Next step for Pfizer teams

If you are on the Pfizer access, medical affairs, or international market access team and want to discuss coordinated named-patient program demand from MENA and India, reach us at [email protected]. We will share aggregated demand views under NDA.

Reserved for you.